The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
J BUON
; 12(2): 245-52, 2007.
Article
em En
| MEDLINE
| ID: mdl-17600880
PURPOSE: The aim of this study was to determine the influence of dexamethasone in the decrease of cisplatin and etoposide-induced nausea and vomiting in patients treated for lung cancer during and after 2 chemotherapy cycles. PATIENTS AND METHODS: The analysis included 60 patients with histologically proven lung cancer, who were divided in two groups. Group A consisted of 30 patients who received cisplatin and etoposide with standard antiemetic drugs: ondansetron [serotonin receptor antagonist (5-HT(3) antagonist)] and metoclopramide (dopamine receptor antagonist). Group B consisted of 30 patients who received the same chemotherapy regimen with the previous antiemetic therapy plus dexamethasone 8 mg intravenously (i.v.) per day during the 3 days of chemotherapy. During and after the 3-day therapy, patients filled in a questionnaire issuing adverse effects of chemotherapy concerning many symptoms including nausea and vomiting. The results were statistically processed. RESULTS: There was a significant decrease in the frequency and toxicity of nausea, acute and delayed vomiting in the group of patients who received antiemetic treatment with ondansetron, metoclopramide plus dexamethasone. CONCLUSION: Dexamethasone administered with 5-HT(3) antagonists and dopamine receptor antagonists significantly decreases the chemotherapy-induced nausea and vomiting.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Vômito
/
Dexametasona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias Pulmonares
/
Antieméticos
/
Náusea
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article